BYSI

BeyondSpring Inc

0.7498

Sep 18 • 3:59 PM ET +0.0410 (5.78%)

0.7498

Aftermarket • 4:15 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: CING EXOZ IBIO IBO IMA IMMP MCRB XBIT FBIO ICCC

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	30.84M
Enterprise Value	24.02M
Income	-6.69M
Sales	0.00M
Book/sh	-0.86
Cash/sh	0.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	44
IPO	Mar 09, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.70
Current Ratio	0.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.16
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	38.52% 37.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	58.89%
Sales Y/Y TTM	-
EPS Q/Q	54.02%
Sales Q/Q	-
Earnings	Mar 25 BMO
EPS/Sales Surpr.	- -

Insider Own	22.31%
Insider Trans	0.00%
Inst Own	5.56%
Inst Trans	0.75%
ROA	-31.92%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.64%
SMA50	-16.92%
SMA200	-48.36%
Trades

Shs Outstand	41.12M
Shs Float	31.95M
Short Float	7.22%
Short Ratio	3.33
Short Interest	2.31M
52W High	2.44 -69.27%
52W Low	0.57 32.54%
Volatility	7.26% 9.01%
ATR (14)	0.07
RSI (14)	48.21
Beta	-0.20
Rel Volume	0.07
Avg Volume	693.35K
Volume	45,286

Perf Week	-1.86%
Perf Month	3.85%
Perf Quarter	-53.43%
Perf Half Y	-51.94%
Perf YTD	-54.00%
Perf Year	-56.41%
Perf 3Y	-9.67%
Perf 5Y	-96.73%
Perf 10Y	-
Recom	2.00
Target Price	1.25
Prev Close	0.71
Price	0.75
Change %	5.78%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-21	Downgrade	Jefferies	Buy → Hold	$38 → $5
Dec-02-21	Downgrade	BofA Securities	Buy → Underperform	$45 → $5
Dec-01-21	Downgrade	William Blair	Outperform → Mkt Perform
Dec-01-21	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-09-21	Initiated	Robert W. Baird	Outperform	$50
Aug-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$100
Apr-05-21	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-21	Initiated	BofA Securities	Buy	$25
Dec-29-20	Initiated	Evercore ISI	Outperform	$30
Feb-07-20	Initiated	Jefferies	Buy	$25
Jan-10-20	Initiated	Nomura	Buy	$34
Dec-03-19	Initiated	William Blair	Outperform
Jul-10-19	Reiterated	H.C. Wainwright	Buy	$60 → $41
Apr-30-19	Downgrade	Maxim Group	Buy → Hold
Oct-25-18	Reiterated	Maxim Group	Buy	$48 → $35

Show Previous Ratings

Aug-14-26 05:15PM	BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -15.78% -15.21%
Jun-04-26 07:00AM	BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value (GlobeNewswire)
Jun-02-26 07:00AM	BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 (GlobeNewswire)
May-18-26 07:00AM	BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting (GlobeNewswire)
May-13-26 09:29AM	BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) (InvestorsHub)
07:00AM	Loading…
07:00AM	BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-22-26 07:00AM	BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs (GlobeNewswire) -6.32%
Mar-30-26 07:30AM	BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 (GlobeNewswire)
Mar-25-26 04:30PM	BeyondSpring Files 2025 Annual Report on Form 10-K (GlobeNewswire)
08:30AM	BeyondSpring Reports 2025 Year-End Financial Results (GlobeNewswire)
Feb-09-26 07:15AM	BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360 Conference (GlobeNewswire)
Dec-12-25 07:00AM	BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path (GlobeNewswire)
Dec-11-25 07:00AM	BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 (GlobeNewswire) +7.92%
Nov-12-25 07:00AM	BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-25 08:00AM	BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment (GlobeNewswire)
07:00AM	Loading…
Jul-07-25 07:00AM	BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure (GlobeNewswire)
Jun-03-25 07:00AM	BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting (GlobeNewswire)
May-28-25 07:00AM	BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting (GlobeNewswire) -5.68%
May-12-25 04:30PM	BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-25 07:05AM	BeyondSpring Files 2024 Annual Report on Form 10-K (GlobeNewswire)
07:00AM	BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones (GlobeNewswire)
Jan-28-25 07:00AM	SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors (GlobeNewswire) +6.04%
07:00AM	BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies (GlobeNewswire)
Nov-11-24 08:00AM	BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting (GlobeNewswire)
Sep-16-24 07:00AM	BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 (GlobeNewswire) -5.22%
07:00AM	BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 (GlobeNewswire)
Sep-10-24 07:00AM	BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine (GlobeNewswire)
Sep-03-24 07:00AM	BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin (GlobeNewswire) -5.39%
Aug-06-24 07:00AM	SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications (GlobeNewswire)
May-21-24 07:49AM	Top Premarket Decliners (MT Newswires)
08:00AM	Loading…
May-16-24 08:00AM	BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics (GlobeNewswire)
May-03-24 07:00AM	BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics (GlobeNewswire)
Apr-29-24 05:30PM	BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results (GlobeNewswire) -9.46%
05:30PM	BeyondSpring Files 2023 Annual Report on Form 20-F (GlobeNewswire)
Mar-25-24 07:00AM	BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer (GlobeNewswire) +11.22%
Feb-26-24 08:00AM	BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements (GlobeNewswire) +9.17%
Jan-10-24 03:00PM	BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K (GlobeNewswire)
Dec-18-23 04:30PM	BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements (GlobeNewswire) -5.94%
Nov-07-23 07:00AM	BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors (GlobeNewswire)
Oct-31-23 08:00AM	BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin's Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models (GlobeNewswire)
Oct-30-23 08:00AM	BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Oct-26-23 08:30AM	SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at Targeted Protein Degradation Think Tank Symposium (GlobeNewswire) -5.36%
Oct-23-23 07:45AM	SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors (GlobeNewswire)
Oct-04-23 03:55PM	BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements (GlobeNewswire)
Sep-27-23 10:00AM	BeyondSpring and Leading Cancer Center to Present Poster at SITC s 38th Annual Meeting (GlobeNewswire)
Sep-07-23 08:00AM	BeyondSpring to Participate in the R.W. Bairds 2023 Global Healthcare Conference (GlobeNewswire)
Jun-20-23 08:00AM	SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors (GlobeNewswire) +8.47%
Jun-07-23 08:00AM	BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulins Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT (GlobeNewswire)
May-22-23 07:44AM	Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? (Simply Wall St.) +5.50%
May-18-23 08:30AM	BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-18-23 04:30PM	BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results (GlobeNewswire) -20.59%
04:30PM	BeyondSpring Files 2022 Annual Report on Form 20-F (GlobeNewswire)
Mar-02-23 05:41AM	BeyondSpring First Half 2022 Earnings: US$0.47 loss per share (vs US$0.93 loss in 1H 2021) (Simply Wall St.)
Mar-01-23 08:00AM	BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy (GlobeNewswire)
Jan-09-23 04:30PM	BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules (GlobeNewswire) +9.20% +20.00%
Dec-20-22 10:43AM	Individual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as well (Simply Wall St.) -35.25%
Dec-13-22 02:57PM	Why Are BeyondSpring Shares Trading Higher? (Benzinga) +35.94%
08:00AM	BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences (GlobeNewswire)
Nov-23-22 04:30PM	BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements (GlobeNewswire)
Sep-13-22 09:57AM	BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours (Benzinga)
07:00AM	BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 (GlobeNewswire)
Aug-29-22 11:33AM	BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients (Benzinga)
07:00AM	BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting (GlobeNewswire)
Jun-27-22 11:01AM	Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains? (Zacks)
Jun-06-22 05:25PM	HealthEquity (HQY) Q1 Earnings Miss Estimates (Zacks) +18.35%
Jun-01-22 07:55AM	Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-27-22 07:00AM	BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting (GlobeNewswire) +16.81%
May-23-22 10:15AM	Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing (GlobeNewswire)
May-17-22 08:45AM	Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Apr-28-22 07:00AM	BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-14-22 01:30PM	BeyondSpring, Inc. (BYSI) Q4 2021 Earnings Call Transcript (Motley Fool) -9.88%
09:04AM	BeyondSpring Files 2021 Annual Report on Form 20-F (GlobeNewswire)
07:00AM	BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-08-22 08:00AM	BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022 (GlobeNewswire) -7.06%
Jan-12-22 05:43AM	BeyondSpring Cuts On-Third Of Its Workforce (Benzinga)
Jan-11-22 04:05PM	BeyondSpring Announces Organizational Streamlining (GlobeNewswire)
Dec-30-21 09:15AM	BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.41%
08:00AM	BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Dec-28-21 10:15AM	BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (ACCESSWIRE)
Dec-15-21 10:23AM	BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia (Benzinga) +6.14%
07:00AM	BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulins Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-14-21 07:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors BeyondSpring Inc. - BYSI (ACCESSWIRE)
Dec-13-21 12:06PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors BeyondSpring Inc. - BYSI (PR Newswire)
Dec-10-21 08:00AM	BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) -7.32%
Dec-06-21 07:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BeyondSpring Inc. - BYSI (GlobeNewswire) +13.63%
Dec-03-21 03:04AM	BeyondSpring: Not Beyond Hope Yet, Says Analyst (TipRanks) -9.46%
Dec-02-21 02:47PM	SHAREHOLDER ALERT: Investigation of BeyondSpring, Inc. Announced by Holzer & Holzer, LLC (Newsfile) -9.94%
10:25AM	BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Dec-01-21 04:45PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of BeyondSpring Inc. (BYSI) Investigation (ACCESSWIRE) -61.39%
01:39PM	BOX Stock: The Good News That Has Box, Inc. Shares Bounding Higher Today (InvestorPlace)
11:45AM	BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (ACCESSWIRE)
08:36AM	BeyondSpring stock plunges after FDA says NDA for CIN treatment 'cannot be approved' in current form (MarketWatch)
08:00AM	BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN) (GlobeNewswire)
Nov-24-21 08:00AM	BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-12-21 08:00AM	BeyondSpring Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-21 07:00AM	BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors (GlobeNewswire)
Oct-22-21 06:13AM	3 Biotech Stocks With Huge Catalysts Incoming (Motley Fool)
Oct-21-21 07:00AM	BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors (GlobeNewswire)
Oct-20-21 07:00AM	BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer (GlobeNewswire)
Oct-15-21 06:50AM	What Type Of Shareholders Make Up BeyondSpring Inc.'s (NASDAQ:BYSI) Share Registry? (Simply Wall St.)

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Co-Founder & Chair of the BoardDr. Lan Huang Ph.D.

Chief Scientific OfficerDr. June Lu Ph.D.

Chief Executive OfficerMr. Min Qiu

Chief Financial OfficerMs. Li Na

Head of Investor RelationsStephen Kilmer

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decheng Capital China Life Sci	10% Owner	Oct 16 '25	Sale	1.72	85,798	147,573	1,564,406	Oct 20 08:00 PM
Decheng Capital China Life Sci	10% Owner	Oct 17 '25	Sale	1.76	45,513	80,103	1,518,893	Oct 20 08:00 PM
Decheng Capital China Life Sci	10% Owner	Oct 13 '25	Sale	1.70	107,361	182,514	1,696,659	Oct 15 08:07 PM
Decheng Capital China Life Sci	10% Owner	Oct 14 '25	Sale	1.65	28,495	47,017	1,668,164	Oct 15 08:07 PM
Decheng Capital China Life Sci	10% Owner	Oct 15 '25	Sale	1.65	17,960	29,634	1,650,204	Oct 15 08:07 PM
Decheng Capital China Life Sci	10% Owner	Oct 08 '25	Sale	1.77	7,507	13,287	1,810,389	Oct 10 05:58 PM
Decheng Capital China Life Sci	10% Owner	Oct 09 '25	Sale	1.81	3,979	7,202	1,806,410	Oct 10 05:58 PM
Decheng Capital China Life Sci	10% Owner	Oct 10 '25	Sale	1.77	2,390	4,230	1,804,020	Oct 10 05:58 PM
Decheng Capital China Life Sci	10% Owner	Oct 06 '25	Sale	1.78	17,500	31,150	1,819,996	Oct 07 06:14 PM
Decheng Capital China Life Sci	10% Owner	Oct 07 '25	Sale	1.79	2,100	3,759	1,817,896	Oct 07 06:14 PM
Decheng Capital China Life Sci	10% Owner	Oct 03 '25	Sale	1.76	600	1,056	1,837,496	Oct 07 06:14 PM
Decheng Capital China Life Sci	10% Owner	Sep 30 '25	Sale	1.81	4,464	8,080	1,841,297	Oct 02 08:51 PM
Decheng Capital China Life Sci	10% Owner	Oct 01 '25	Sale	1.80	2,601	4,682	1,838,696	Oct 02 08:51 PM
Decheng Capital China Life Sci	10% Owner	Oct 02 '25	Sale	1.73	600	1,038	1,838,096	Oct 02 08:51 PM
Decheng Capital China Life Sci	10% Owner	Sep 25 '25	Sale	1.66	700	1,162	1,846,861	Sep 29 08:06 PM
Decheng Capital China Life Sci	10% Owner	Sep 26 '25	Sale	1.68	600	1,008	1,846,261	Sep 29 08:06 PM
Decheng Capital China Life Sci	10% Owner	Sep 29 '25	Sale	1.75	500	875	1,845,761	Sep 29 08:06 PM
Decheng Capital China Life Sci	10% Owner	Sep 22 '25	Sale	1.83	5,410	9,900	1,853,923	Sep 24 06:49 PM
Decheng Capital China Life Sci	10% Owner	Sep 23 '25	Sale	1.72	4,106	7,062	1,849,817	Sep 24 06:49 PM
Decheng Capital China Life Sci	10% Owner	Sep 24 '25	Sale	1.68	2,256	3,790	1,847,561	Sep 24 06:49 PM
Decheng Capital China Life Sci	10% Owner	Sep 19 '25	Sale	1.79	3,656	6,544	1,859,333	Sep 19 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BYSI

BeyondSpring Inc

Upgrade your Finviz experience